 NEW YORK, March 3, 2021 PRNewswire -- Hoth Therapeutics, Inc. NASDAQ: HOTH, a patient focused clinical stage biopharmaceutical company, today provided an update on preclinical study on HT-002 for the prevention andor treatment of Sars-CoV-2, or COVID-19. The novel peptide... 